Literature DB >> 7887450

Expression of receptors for advanced glycation end products in peripheral occlusive vascular disease.

U Ritthaler1, Y Deng, Y Zhang, J Greten, M Abel, B Sido, J Allenberg, G Otto, H Roth, A Bierhaus.   

Abstract

The cellular interactions of advanced glycation end products (AGEs), which have been hypothesized to contribute to the development of vascular lesions, occur, at least in part, through their binding to a novel integral membrane protein, the receptor for AGEs (RAGE). Studies of human vascular segments show that endothelial RAGE expression at the antigen and mRNA level was variable and usually at low levels in samples from healthy individuals. In contrast, patients with a range of peripheral occlusive vascular diseases, with or without underlying diabetes, demonstrated prominent enhancement of endothelial RAGE expression. Smooth muscle cells and nerves in the vessel wall showed constitutively high levels of RAGE expression that were unchanged with aging (from 1 to 92 years) or by the presence of vascular disease. These data suggest that RAGE is likely to have ligands other than AGEs, and that multiple factors in addition to AGEs impact on its expression. Taken together, our findings suggest that RAGE may contribute to the pathogenesis of a range of vascular disorders.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7887450      PMCID: PMC1869189     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  27 in total

1.  Angiogenic effects of advanced glycation end products of the Maillard reaction on cultured human umbilical cord vein endothelial cells.

Authors:  M Tezuka; N Koyama; N Morisaki; Y Saito; S Yoshida; N Araki; S Horiuchi
Journal:  Biochem Biophys Res Commun       Date:  1993-06-15       Impact factor: 3.575

Review 2.  Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications.

Authors:  M Brownlee; A Cerami; H Vlassara
Journal:  N Engl J Med       Date:  1988-05-19       Impact factor: 91.245

3.  Advanced glycation end products contribute to amyloidosis in Alzheimer disease.

Authors:  M P Vitek; K Bhattacharya; J M Glendening; E Stopa; H Vlassara; R Bucala; K Manogue; A Cerami
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-24       Impact factor: 11.205

4.  Receptor for advanced glycation end products (AGEs) has a central role in vessel wall interactions and gene activation in response to circulating AGE proteins.

Authors:  A M Schmidt; M Hasu; D Popov; J H Zhang; J Chen; S D Yan; J Brett; R Cao; K Kuwabara; G Costache
Journal:  Proc Natl Acad Sci U S A       Date:  1994-09-13       Impact factor: 11.205

5.  Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins.

Authors:  S D Yan; A M Schmidt; G M Anderson; J Zhang; J Brett; Y S Zou; D Pinsky; D Stern
Journal:  J Biol Chem       Date:  1994-04-01       Impact factor: 5.157

6.  Glycated tau protein in Alzheimer disease: a mechanism for induction of oxidant stress.

Authors:  S D Yan; X Chen; A M Schmidt; J Brett; G Godman; Y S Zou; C W Scott; C Caputo; T Frappier; M A Smith
Journal:  Proc Natl Acad Sci U S A       Date:  1994-08-02       Impact factor: 11.205

7.  Advanced glycation end products (AGEs) on the surface of diabetic erythrocytes bind to the vessel wall via a specific receptor inducing oxidant stress in the vasculature: a link between surface-associated AGEs and diabetic complications.

Authors:  J L Wautier; M P Wautier; A M Schmidt; G M Anderson; O Hori; C Zoukourian; L Capron; O Chappey; S D Yan; J Brett
Journal:  Proc Natl Acad Sci U S A       Date:  1994-08-02       Impact factor: 11.205

8.  Glucosylation of human collagen in aging and diabetes mellitus.

Authors:  S L Schnider; R R Kohn
Journal:  J Clin Invest       Date:  1980-11       Impact factor: 14.808

9.  Cachectin/TNF and IL-1 induced by glucose-modified proteins: role in normal tissue remodeling.

Authors:  H Vlassara; M Brownlee; K R Manogue; C A Dinarello; A Pasagian
Journal:  Science       Date:  1988-06-10       Impact factor: 47.728

10.  Endothelial receptor-mediated binding of glucose-modified albumin is associated with increased monolayer permeability and modulation of cell surface coagulant properties.

Authors:  C Esposito; H Gerlach; J Brett; D Stern; H Vlassara
Journal:  J Exp Med       Date:  1989-10-01       Impact factor: 14.307

View more
  37 in total

Review 1.  [Non-enzymatic glycation and oxidative stress in chronic illnesses and diabetes mellitus].

Authors:  P P Nawroth; A Bierhaus; G E Vogel; M A Hofmann; M Zumbach; P Wahl; R Ziegler
Journal:  Med Klin (Munich)       Date:  1999-01-15

2.  Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response.

Authors:  Birgit Liliensiek; Markus A Weigand; Angelika Bierhaus; Werner Nicklas; Michael Kasper; Stefan Hofer; Jens Plachky; Herman-Josef Gröne; Florian C Kurschus; Ann Marie Schmidt; Shi Du Yan; Eike Martin; Erwin Schleicher; David M Stern; G ünterJ Hämmerling G; Peter P Nawroth; Bernd Arnold
Journal:  J Clin Invest       Date:  2004-06       Impact factor: 14.808

Review 3.  [Urosepsis and treatment].

Authors:  F M E Wagenlehner; C Lichtenstern; M A Weigand; W Weidner
Journal:  Urologe A       Date:  2010-05       Impact factor: 0.639

4.  Ager Deletion Enhances Ischemic Muscle Inflammation, Angiogenesis, and Blood Flow Recovery in Diabetic Mice.

Authors:  Raquel López-Díez; Xiaoping Shen; Gurdip Daffu; Md Khursheed; Jiyuan Hu; Fei Song; Rosa Rosario; Yunlu Xu; Qing Li; Xiangmei Xi; Yu Shan Zou; Huilin Li; Ann Marie Schmidt; Shi Fang Yan
Journal:  Arterioscler Thromb Vasc Biol       Date:  2017-06-22       Impact factor: 8.311

Review 5.  Age-related changes affecting atherosclerotic risk. Potential for pharmacological intervention.

Authors:  L G Spagnoli; A Mauriello; A Orlandi; G Sangiorgi; E Bonanno
Journal:  Drugs Aging       Date:  1996-04       Impact factor: 3.923

Review 6.  Understanding RAGE, the receptor for advanced glycation end products.

Authors:  Angelika Bierhaus; Per M Humpert; Michael Morcos; Thoralf Wendt; Triantafyllos Chavakis; Bernd Arnold; David M Stern; Peter P Nawroth
Journal:  J Mol Med (Berl)       Date:  2005-08-24       Impact factor: 4.599

7.  Advanced glycation end products cause epithelial-myofibroblast transdifferentiation via the receptor for advanced glycation end products (RAGE).

Authors:  M D Oldfield; L A Bach; J M Forbes; D Nikolic-Paterson; A McRobert; V Thallas; R C Atkins; T Osicka; G Jerums; M E Cooper
Journal:  J Clin Invest       Date:  2001-12       Impact factor: 14.808

8.  Association between carotid diameter and the advanced glycation end product N-epsilon-carboxymethyllysine (CML).

Authors:  Marcus Baumann; Tom Richart; Daniel Sollinger; Jaroslav Pelisek; Marcel Roos; Tatiana Kouznetsova; Hans-Henning Eckstein; Uwe Heemann; Jan A Staessen
Journal:  Cardiovasc Diabetol       Date:  2009-08-06       Impact factor: 9.951

Review 9.  Multiple levels of regulation determine the role of the receptor for AGE (RAGE) as common soil in inflammation, immune responses and diabetes mellitus and its complications.

Authors:  A Bierhaus; P P Nawroth
Journal:  Diabetologia       Date:  2009-07-28       Impact factor: 10.122

10.  Advanced glycation end products and the absence of premature atherosclerosis in glycogen storage disease Ia.

Authors:  N C den Hollander; D J Mulder; R Graaff; S R Thorpe; J W Baynes; G P A Smit; A J Smit
Journal:  J Inherit Metab Dis       Date:  2007-06-14       Impact factor: 4.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.